GSDMD and mastitis: Furthermore, PANoptosis activation is the main pathway and an effective therapeutic target during mastitis disease progression, and GSDMD activation is a key factor contributing to the BMB damage during mastitis, while C3Gal can inhibit its NT activity (Figure 9).